SEMA3F and ductal breast carcinoma in situ: To evaluate the potential role of SEMA3F-NRP1/NRP2 as therapeutic targets and prognostic markers in the DCIS stage of BC and to start moving our results from bench to bedside, gene expression data from tumors from all BC stages in the GOBO database were analysed.